Abstract
The risk of cancer in users of verapamil was assessed in a long-term follow-up of 1,775 patients who were randomized to verapamil or matching placebo in the Danish Verapamil Infarction Trial-II in the years 1985 to 1987. During 10,474 patient-years, no increased risk of cancer was observed for the verapamil-treated men or women compared with the age- and sex-matched background population.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Calcium Channel Blockers / adverse effects*
-
Calcium Channel Blockers / therapeutic use
-
Coronary Disease / drug therapy
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoplasms / chemically induced*
-
Randomized Controlled Trials as Topic
-
Risk
-
Verapamil / adverse effects*
-
Verapamil / therapeutic use
Substances
-
Calcium Channel Blockers
-
Verapamil